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The aim of the present study was to enhance the dissolution rate of an NSAID drug Ketoprofen by formulating 
it into solid dispersions with water soluble carrier Poloxamer 188 and Eudragit S 100. The solid dispersions 
of Ketoprofen with Poloxamer 188 were prepared at 1:1, 1:1.5 and 1:2 (Ketoprofen: Poloxamer 188) ratio 
by Solvent evaporation methods. The same concentration ratio was used for the preparation of solid 
dispersion with Eudragit S 100 by melting/fusion technique. Further, solid dispersions were investigated 
by solubility, ATR-FTIR, XRD, DSC, surface morphology, in-vitro dissolution and accelerated stability 
study. Results demonstrated that both Poloxamer 188 and Eudragit S 100 improve solubility of drugs by 
8–10 folds. The result of ATR-FTIR study showed the slight shifting/broadening of principle peaks. In 
vitro dissolution studies showed that in the solid dispersion system containing Ketoprofen: Poloxamer 188 
batch P2 (1:1.5) gives faster dissolution rate of Ketoprofen than the physical mixtures. The solid dispersion 
with Eudragit S 100, batch E1 (1:1) gives faster dissolution rate of Ketoprofen than the physical mixtures. 
In phase solubility study with Poloxamer 188 showed concentration dependent solubilization of drug but 
Eudragit S 100 produced opposite result. The effect of pH on solubility of Eudragit S 100 was carried out 
which showed solubility at pH 7.4. The dissolution profile of solid dispersion with Eudragit S 100 at pH 7.4 
gives excellent result. The Accelerated stability of solid dispersions & its physical mixtures were studied 
at 400±2 °C/75 ± 5% RH for a period of 1 month. In these studies, Solid Dispersion batches produced an 
unstable formulation. The Ketoprofen solid dispersions with Poloxamer 188 and Eudragit S 100 could be 
introduced as a suitable form with improved solubility.
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INTRODUCTION
The aqueous solubility of a drug is a significant 
limitation to its oral absorption. Poorly water-soluble 
drugs are associated with slow drug absorption leading 
ultimately to inadequate and variable bioavailability 
(Amidon et al., 1995; Leuner, Dressman, 2000). The 
Biopharmaceutical Classification System (BCS) is the 
scientific framework for classifying drug substances 
based on their aqueous solubility and intestinal 
permeability. BCS class II and IV drugs which have low 
solubility provide a number of challenges for formulation 
and scientists are constantly working on the oral delivery 
of these drugs (Lobenberg, Amidon, 2000). Oral intake 
is the most convenient and commonly used route of drug 
delivery due to its convenience of administration, high 
patient compliance, cost-effectiveness, least sterility 
constraints and flexibility in the design of dosage 
form. As a result, many of the generic drug companies 
are inclined more to produce bioequivalent oral drug 
products. (Blagden, De Matas, Gavan, 2007)
Solid Dispersion (SD) technique has been extensively 
used to improve the dissolution rate, solubility and oral 
absorption of poorly water-soluble drugs. The dispersion 
method allows preparation of physically modified forms 
of drug that is much more rapidly soluble in water 
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than pure compound. Solid Dispersion is defined as a 
dispersion of one or more active ingredients in an inert 
carrier or matrix at solid state. (Abu, 1999; Chiou, 
Riegelman, 1971; Dehghan, Jafar, 2006; Jachowicz, 
Nurnberg, Pieszezek, 2000; Patil et al., 2010)
Ketoprofen is an NSAIDs BCS Class II drug and 
used for the treatment of rheumatoid arthritis with well-
known antipyretic and analgesic properties as well as 
treatment of mild to moderate pain (Kim, Choi, 2002). 
Also, it is an inhibitor of prostaglandin synthetase 
(Yalcin, Gulgun, Umit, 1999). However, it is practically 
insoluble in water and causes systemic disorder in the 
gastrointestinal tract (Jachowicz, Nurnberg, Pieszezek, 
2000). So that the improvement of its solubility and oral 
bio-availability remains one of the most challenging 
aspects of drug development mainly for oral drug delivery 
system. The in vivo and in vitro characteristics and the 
problems in achieving conventional and reproducible in 
vivo/in vitro relationship are often suitably difficult to 
develop formulation due to solubility issue. One way to 
enhance the solubility of poorly soluble drugs is through 
the formation of solid dispersion.
With these, we have carried out a study to enhance 
the solubility of Ketoprofen through the preparation 
of its solid dispersions with Poloxamer 188 and 
Eudragit S 100. Further, SDs were evaluated by Phase 
solubility, Infrared spectroscopy (ATR-FTIR), X-ray 
diffraction (XRD), Differential Scanning Calorimetry 
(DSC), scanning electron microscopy (SEM), in vitro 
dissolution studies and accelerated stability study.
MATERIAL AND METHODS
Material
Ketoprofen was received as a gift sample from BEC 
Chemical Ltd (Roha, Raigad, Maharashtra). Poloxamer 
188 and Eudragit S 100 were from Fine Laboratories 
(Mumbai) and all other materials and reagents used 
were of analytical grade.
Phase solubility study
Phase-solubility studies were carried out by adding 
an excess of drug (20 mg) in 10 mL of aqueous solution of 
different (1:0, 1:1, 1:2, 1:4, 1:6, 1:8 and 1:10) Poloxamer 
188 and Eudragit S 100 polymer concentrations. 
The suspensions were continuously stirred on an 
electromagnetic stirrer at 370 ºC and 300 rpm for 48 h. 
The suspensions were filtered through a Whatman filter 
paper no. 0.45 micron. The filtrates were suitably diluted 
and analyzed by UV Spectrophotometry at 256 nm.
The Gibbs free energy of transfer (DG0tr) of 
Ketoprofen from pure water to the aqueous solution of 
the carrier was calculated as follows:
ΔG0tr= -2.303 RT log S0/SS
Where, S0/SS is the ratio of molar solubility of 
Ketoprofen in aqueous solutions of the carrier to that of 
the same medium without a carrier.





Where slope and intercept was obtained from the 
graph of % w/v of Ketoprofen Vs aqueous concentration 
of carrier (poloxamer188/Eudragit S 100 in % w/v). 
In reported literature, it was observed that Eudragit, 
S 100 is soluble and releases active ingrents at pH 6.5 
and above (Mehta et al., 2013; Sonje, Chandra, 2013). 
To further check this phenomenon we have carried out 
phase solubility study at different pH i.e. 2.4, 3.4, 5.4 and 
7.4 in phosphate buffer. 
Preparation of solid dispersion
Solvent evaporation method
The solid dispersion of Ketoprofen and Poloxamer 
188 was prepared with different concentrations of drug 
& carrier by dissolving in common solvent i.e. Ethanol. 
Then the solvent was evaporated at 40 °C, obtained 
mass was preserved in well-closed glass containers in 
desiccators under vacuum (by using anhydrous CaCl2) 
at 18-20 °C for 2 days. Prepared formulation was crushed 
& passed through sieve mesh no. 20.
Melting/Fusion method
The solid dispersion of Ketoprofen and Eudragit S 
100 was prepared by heating drug and a carrier directly 
until it melted. The melted mixture was then cooled and 
solidified rapidly in an ice bath under vigorous stirring. 
The prepared formulation was milled & passed through 
sieve no. 20.
Screening of Ketoprofen-Poloxomer and Ketoprofen-Eudragit solid dispersions for improved Physicochemical characteristics and dissolution profile
Braz. J. Pharm. Sci. 2020;56: e18641 Page 3/19
Preparation of a physical mixture
A physical mixture of Ketoprofen and Poloxamer 
188 was prepared separately by thoroughly mixing 
the two components in a mortar for 15 min until a 
homogeneous mixture was obtained. Dry mass was 
pulverized and sieved through sieve mesh no. 20.
The Table I summarizes the concentrations of drug 
and carrier in different batches of physical mixture and 
solid dispersions.
Attenuated total reflectance fourier transform 
infrared spectroscopy (ATR-FTIR)
ATR-FTIR spectra of solid dispersion with 
their physical mixtures were obtained using ATR-
FTIR spectrophotometer (carry 630 FTIR, Agilent 
technologies). The scanning range was 400-4000 cm-1.
In vitro dissolution study
Preparation of dissolution media
0.1N HCl: 8.33 ml of conc. HCl was dissolved in 
1000 ml of distilled water.
The dissolution test of prepared solid dispersions, 
physical mixtures and plain Ketoprofen was performed 
using the United States Pharmacopoeia (USP) dissolution 
apparatus II at 50 rpm. Formulations were placed in the 
dissolution vessel containing 1000 mL of 0.1 N HCl in 
purified water maintained at 37±0.5 ºC. Samples from the 
dissolution medium were withdrawn and concentrations 
were determined by the spectrophotometric method 
at 256 nm. The dissolution study was carried out in 
triplicate and the plot of mean values versus time was 
obtained. For Eudragit S 100 the dissolution study was 
repeated at pH 7.4.
Differential Scanning Calorimetry (DSC)
DSC was carried out to detect crystalline nature. 
About 3-5 mg of sample in 100 µL aluminum pan was 
measured with a DSC 1 (Mettler-Toledo, DSC 1 star 
system, Mumbai, India). A scanning rate of 10 ºC min-1 
and a nitrogen gas flow of 40 ml/min were applied. The 
measurement was conducted in a temperature range of 
400 to 150 ºC.
X-Ray Diffraction (XRD)
To determine the physical state of pure Ketoprofen, 
solid dispersion and physical mixture, X-ray diffraction 
study was carried out. A transmission diffractometer 
(rigaku miniflex, Mumbai, India) was used to investigate 
crystalline nature in prepared solid dispersion, physical 
mixture and Ketoprofen. Diffraction patterns were 
obtained at a voltage of 45 kV and at a current of 40 
mA. Samples were scanned in a 2 θ range from 50 to 
700 with a scanning speed of 20/min and an intensity 
of 1000 cps.
Scanning Electron Microscopy (SEM)
The surface morphology of the solid dispersion, 
physical mixture and pure Ketoprofen was analyzed by 
a scanning electron microscope model JEOL, JSM-5400 
(Japan) coupled with energy dispersive X-ray analysis 
(EDAX).
Accelerate stability study
Accelerated stability study was carried out by 
storing optimized batches of solid dispersions and 
physical mixtures at 400±2 °C/75 ± 5% RH for 1 month 
in a stability chamber. All the preparations were studied 
TABLE I - Drug & polymer conc. ratio for solid dispersions and physical mixtures 
Batch no.
Solid Dispersion Batch  
no.
Physical Mixture Batch  
no.
Solid Dispersion Batch  
no.
Physical Mixture
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for their physical characterization, λmax, calibration 
curve, ATR-FTIR and in-vitro dissolution studies.
RESULT AND DISCUSSION
Phase solubility studies
The plots of drug solubility against the polymer 
concentration (Figure 1) indicate a linear relationship 
in the investigated polymer concentration range. Gibbs 
free energy of transfer (ΔG0tr) and apparent stability 
constants (Ka) derived from figure 1 are shown in Table 
II which show that all values of ΔG0tr were negative at 
all levels of carrier’s i.e. Poloxamer 188 demonstrating 
spontaneity of drug solubilization process. The values 
show a declining trend with an increase in the carrier 
concentration too construing that the process is more 
favorable at higher carrier levels. The result shows that the 
solubility of Ketoprofen increased with increasing carrier 
concentration. The phase solubility plots of drug solubility 
against the polymer Eudragit S 100 concentration 
(Figure 2) indicate, there is no linear relationship in the 
investigated polymer concentration range. The pH versus 
solubility profile of Eudragit S 100 is given in figure 3, 
which indicates that increase in pH increases the solubility 
of Eudragit S 100. The highest solubility was observed 
at pH 7.4 which was 94%. Then the phase solubility was 
calculated at pH 7.4 for Eudragit S 100 and Gibbs free 
energy of transfer (ΔG0tr) and apparent stability constants 
(Ka) derived from figure 4 are shown in Table II. Table II 
shows that the values of ΔG0tr were negative at all levels 
of carriers, demonstrating that the drug solubilization 
process is more favorable at higher concentrations. It was 
observed that pH affects on phase solubility of drug with 
Eudragit S 100. At pH 7.4 all the values of ΔG0tr were 
negative at all levels of Eudragit S 100.
TABLE II - Gibbs free energy values and apparent stability 












S 100 at pH 7.4
5 -7.38 42.83 -8.63
(continuing)
TABLE II - Gibbs free energy values and apparent stability 












S 100 at pH 7.4
10 -17.96 34.60 -20.03
20 -31.70 29.38 -27.91
30 -32.07 28.63 -36.71
40 -32.94 24.48 -36.80
50 -34.33 24.29 -37.12
Intercept 0.4838 0.2266 0.5129
Slope 0.0119 -0.0011 0.0178
Ka 0.0250 -0.0048 0.0273
Drug content



















1 P1 1:1 83.11% E1 1:1 91.06%
2 P2 1:1.5 92.02% E2 1:1.5 85.25%
3 P3 1:2 87.79% E3 1:2 87.93%
The solid dispersion of Ketoprofen: Poloxamer 
188 by the solvent evaporation method showed drug 
content of 83.11 to 92.02%. The % drug content of solid 
dispersions prepared by solvent evaporation technique is 
shown in Table II. The drug content of batch P1 (1:1) was 
83.11 %, batch P2 (1:1.5) was 92.02% & batch P3 (1:2) 
was 87.79%. The batch P2 produced high % drug content 
than batch P1 and P3 respectively. The solid dispersion 
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by Melting methods using Eudragit S 100 compositions 
has a drug content of 85.25 to 91.06% (Table II). The 
drug content of batch E1 (1:1) was 91.06%, batch E2 
(1:1.5) was 85.25% & batch E3 (1:2) was 87.93%. The 
batch E1 produced high % drug content than batch E2 
and E3 respectively. 
FIGURE 1 - Phase solubility of Ketoprofen:Poloxamer 188. 
FIGURE 2 - Phase solubility of Ketoprofen:Eudragit S-100. 
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FIGURE 3 - % Solubility of Eudragit S 100 at different pH.
FIGURE 4 - Phase solubility of Ketoprofen:Eudragit S-100 at pH 7.4.
ATR-FTIR spectroscopy
The FTIR spectrum of Ketoprofen was recorded 
using FTIR (Cary-630 Agilent technology), band 
were observed at 3050.166 cm-1 (O-H stretching), 
2644.006 cm-1 (C- H stretching.), 1284.104 cm-1 
(C-H deformation), 1695.602 cm-1 (C=O stretching), 
787.989 cm-1 (Aromatic-H). The spectra are shown in 
Figure 5 and 6. The IR studies of SDs & physical mixtures 
revealed that there is not any chemical interaction 
between Ketoprofen & Poloxamer 188 and Eudragit 
S 100 observed.
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FIGURE 5 - ATR-FTIR of Ketoprofen, physical mixtures and solid dispersions with Poloxomer 188.
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FIGURE 6 - ATR-FTIR of Ketoprofen, physical mixtures and solid dispersions with Eudragit S 100
Screening of Ketoprofen-Poloxomer and Ketoprofen-Eudragit solid dispersions for improved Physicochemical characteristics and dissolution profile
Braz. J. Pharm. Sci. 2020;56: e18641 Page 9/19
In vitro drug dissolution study
The dissolution profile of Ketoprofen, different 
concentration of physical mixtures and solid dispersions 
with polaoxamer 188 in 0.1 N HCl as a dissolution 
medium is shown in Figure 7. The result indicates 
that pure Ketoprofen, physical mixture of Ketoprofen: 
Poloxamer 188 (1:1) batch P1p and solid dispersion 
batch P1 (1:1) showed 27.91±0.015, 61.53±0.0256 
and 89.64±0.236% CDR after 90 min respectively. 
The physical mixture of Ketoprofen: Poloxamer 188 
batch P2p (1:1.5) and solid dispersion batch P2 (1:1.5) 
showed 65.99±0.056 and 91.83±0.563% CDR after 90 
min respectively. The physical mixture of Ketoprofen: 
Poloxamer 188 batch P3p (1:2) and solid dispersion 
batch P3 (1:2) showed 67.99±0.123 and 90.98±0.124% 
CDR after 90 min respectively. It is evident that the solid 
dispersion technique improved the dissolution rate of 
the drug to a great extent than a physical mixture. The 
result indicates that Ketoprofen: Poloxamer 188 in the 
batch P2 (1:1.5) showed 91.83% drug release in 90 min 
which was the highest dissolution rate followed by the 
batch P1 (89.64%) & batch P3 (90.98%). 
The dissolution profile of Ketoprofen, Physical 
mixtures, prepared solid dispersions with Eudragit S 
100 in 0.1 N HCl as a dissolution medium is shown 
in figure 8. The result indicates that pure Ketoprofen, 
physical mixture of Ketoprofen: Eudragit S 100 
batch E1p (1:1) and solid dispersion batch an E1 (1:1) 
produced 27.91±0.015, 58.09±0.015 and 89.72±0.640% 
CDR after 90 min respectively. The physical mixture of 
Ketoprofen: Eudragit S 100 batch E2p (1:1.5) and solid 
dispersion batch E2 ratio (1:1.5) produced 62.25±0.060 
and 85.54±0.139% CDR after 90 min respectively. 
The physical mixture of Ketoprofen: Eudragit S 100 
batch E3p (1:2) and solid dispersion batch E3 (1:2) 
produced 64.89±0.392 and 86.45±0.382% CDR 
after 90 min respectively. Solid dispersion technique 
improved the dissolution rate of the drug to a great 
extent than Physical mixture. The result indicates that 
Ketoprofen: Eudragit S 100 in batch E1 (1:1) showed 
89.72% drug dissolution in 90 min which was the 
highest dissolution rate followed by batch E2 (85.54%) 
& batch E3 (86.45%). At pH 7.4 the Eudragit S 100 
produced maximum drug release which was found to 
be 96.23±0.810% CDR for batch E3 (1:2), at same pH 
physical mixture showed E3p 68.61±0.102% CDR. 
The result has been given in Figure 8.
Differential Scanning Calorimetry (DSC).
The thermal analysis by DSC, usually offers 
information about several physicochemical properties 
such as crystalline nature and thermal stability. The 
thermogram of the unprocessed Ketoprofen (Figure.9a) 
exhibited a sharp endothermic peak at temperature 
98.09 °C with (enthalpy change) ΔH = 76.40 J/g and 
ΔHm = 1942 kJmoles-1. The sample shows melting 
onset temperature i. e. Tonset = 92.90 ºC. The DSC 
thermogram of the physical mixture of the batch P2p 
(1:1.5) (fig. 9b) showed a slight change in melting point 
recording with peak temperature 95.68 °C and enthalpy 
change ΔH = 73.61 J/g and ΔHm = 18.71 kJmoles-1. The 
melting point of 52.65 ºC was observed in the DSC 
thermogram of a solid dispersion of batch P2 (1:1.5) 
(Figure 9c). The change in enthalpy (ΔH) = 42.81 J/g 
and ΔHm = 10.88 kJmoles-1. It is observed that there is a 
disappearance of the endothermic peak and also changes 
in peak intensity when compared with thermogram of 
pure Ketoprofen & physical mixture. The absence of 
endothermic peak might be due to the formation of the 
solid dispersion of the drug in the presence of Poloxamer 
188 polymer, where the drug could be transformed into 
an amorphous state. The melting point and enthalpy 
change (ΔH) of crystalline pure Ketoprofen was 
98.09 °C & 76.40 J/g respectively. The melting point and 
enthalpy change (ΔH) for solid dispersion was observed 
as 52.65 ºC and 42.81 J/g respectively. 
The DSC thermogram of the physical mixture of 
the batch E1p (1:1) (Figure 9d) showed slightly change 
in melting point recording with peak temperature 
95.37 °C and change in enthalpy ΔH = 73.50 J/g and ΔHm 
= 18.68 kJ moles-1. In the DSC thermogram of a solid 
dispersion of batch E1 (1:1) (Figure 9e) showed a change 
in the melting point recording with peak temperature 
89.27°C and change in enthalpy ΔH = 64.10 J/g and 
ΔHm = 16.29 kJ moles-1. Here also the disappearance 
of the endothermic peak observed. The change in peak 
intensity compare than thermogram of Ketoprofen 
& physical mixture of batch E1p was recorded. DSC 
studies also showed that there no interaction between 
drug and carrier at a molecular level in both the solid 
dispersions and physical mixtures
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FIGURE 7 - Dissolution profile of Ketoprofen, physical mixture and solid dispersion with Polaxamer 188.
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FIGURE 8 - Dissolution profile of Ketoprofen, physical mixture and solid dispersion with Eudragit S 100.
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(continuing)
Screening of Ketoprofen-Poloxomer and Ketoprofen-Eudragit solid dispersions for improved Physicochemical characteristics and dissolution profile
Braz. J. Pharm. Sci. 2020;56: e18641 Page 13/19
(continuing)
Ravi Yashwant Savardekar, Amol Shantinath Sherikar
Page 14/19 Braz. J. Pharm. Sci. 2020;56: e18641
FIGURE 9 - (a) DSC of Ketoprofen at temp. 98.09 °C. (b) DSC of Physical Mixture of Batch P2p [Ketoprofen: Polo (1:1.5)] 
at temp. 95.68 °C. (c) DSC of Solid Dispersion of Batch P2 [Ketoprofen: Polo (1:1.5)] at temp. 52.65 °C. (d) DSC of Physical 
Mixture of Batch E1p [Ketoprofen: Eud (1:1)] at temp. 95.37°C. (e) DSC of Solid Dispersion of Batch E1 [Ketoprofen: Eud (1:1)] 
at temp. 89.27 °C.
X-Ray Diffraction (XRD)
The distinct, high, intense peaks were observed in 
X-Ray diffraction of pure Ketoprofen (Figure 10a) in the 
range of 5-50º 2θ, indicating the highly crystalline nature 
of the drug. It showed distinct peaks approximately at 
13, 15, 17 and 23º 2θ. In X-ray diffraction pattern of 
physical mixture batch P2p (1:1.5) (Figure 10b) intense 
peaks were observed at 18 and 23º 2θ, which did not 
show any change in crystallinity. The X-ray diffraction 
pattern of solid dispersion of batch P2 (1:1.5) (Figure 
10c) showed intense peaks at 18 and 23º 2θ. The X-ray 
diffraction pattern of physical mixture batch E1p (1:1) 
(Figure 10d) produced a single broad peak in the range 
of 8 to 23º 2θ, whereas X-ray diffraction pattern of 
solid dispersion of batch E1 (1:1) (Figure 10e) produced 
two broad peaks in the range of 8 to 23º 2θ and 25 to 
38º 2θ. Moreover, the 2θ angle of these peaks remained 
practically unchanged. However, the X-ray diffraction 
of solid dispersion did not show any intense peak that is 
characteristic of the crystal structure. It reflects that the 
drug was essentially converted from high crystalline to 
moderate form. The results also suggest that there may 
be a mild interaction between Ketoprofen and Poloxamer 
188, Eudragit S 100 in solid dispersion which changes 
orientation during crystal growth phase. IR and DSC 
studies support the same hypothesis, which is confirmed 
by X-ray diffractometry
Scanning Electron Microscopy (SEM)
Figure 11 depicts SEM images of pure Ketoprofen the 
bar on the pictures indicates the degree of magnification 
50 µm. The SEM of pure Ketoprofen showed irregular 
shape crystals of rough surfaces. SEM images of a 
physical mixture of batch P2p (1:1.5) showed slightly 
irregular shape. SEM images of a solid dispersion of 
batch P2 (1:1.5) at magnification 50 µm did not have 
any irregular shapes and crystalline nature of the drug, 
which can be because of entrapment of drug within the 
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polymer i.e. Poloxamer 188. SEM of a physical mixture 
of batch E1p (1:1) showed slightly irregular shape at 
magnification 50 µm. SEM of a solid dispersion of batch 
E1 (1:1) showed non- crystalline nature of the drug, 
which can be because of entrapment of drug within the 
polymer i.e. Eudragit S 100. 
The whole study of SEM showed a smooth surface 
of Ketoprofen with Poloxamer 188 and Eudragit S 100, 
by using solid dispersion there may be a complete coating 
of Ketoprofen with polymer particles. Solid dispersion 
particles looked like irregularly shaped matrices which 
suggest that particle shape and surface topography is 
changed during formation of the solid dispersion. These 
findings demonstrate that reduction in particle size, 
increased surface area and close contact between drug 
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FIGURE 10 - (a) XRD of Ketoprofen. (b) XRD of Physical Mixture of Batch P2p [Ketoprofen: Polo (1:1.5)]. (c) XRD of Solid 
dispersion of Batch P2 [Ketoprofen: Polo (1:1.5)]. (d) XRD of Physical Mixture of Batch E1p [Ketoprofen: Eud (1:1)]. (e) XRD 
of Solid Dispersion of Batch E1 [Ketoprofen: Eud (1:1)]. 
(e)
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FIGURE 11 - SEMs of Ketoprofen, Physical mixtures and Solid dispersions.
Accelerate stability study
Effect of temperature: At 40 °C (Short Term)
It is recognized that amorphous drugs formulated 
in the form of a solid dispersion with its physical mixture 
tend to recrystallizes on storage. To check the effect of 
temperature & time, stability testing was performed 
according to ICH guidelines “stability testing of new 
drug substances and products Q1A (R2)” (ICH, 2003). 
The samples were stored at 400 ºC /75% RH for 1 month 
in high-density polyethylene bottles. The results showed 
in a physical mixture of batch P2p (1:1.5) produced 
39.56±0.123% CDR and solid dispersion batch P2 (1:1.5) 
produced 20.78±0.124% CDR. The batch E1P (1:1) 
produced 65.23±0.521% CDR, while solid dispersion 
batch E1 produced 70.35±0.652% CDR. The physical 
mixture and solid dispersion showed changes in color 
and appearance in accelerated stability study. 
From the result of the accelerated stability study, it 
can be concluded that the drug, physical mixtures and 
solid dispersions may undergo degradation.
CONCLUSION
Solid dispersion technique was used to improve 
physical characteristics and dissolution profile of 
Ketoprofen. Poloxamer 188 and Eudragite S 100 
were used as a carrier to improve physicochemical 
characteristics and dissolution profile of ketoprofen. 
Solid dispersion technique was found to be effective in 
increasing the aqueous solubility of ketoprofen. In vitro 
dissolution studies showed that in the solid dispersion 
system gave faster dissolution rate than physical 
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This is an open-access article distributed under the terms of the Creative Commons Attribution License. 
mixtures. In accelerated stability study a significant 
change in various parameters like color, physical 
appearance, % CDR was observed, which indicates that 
these formulations are unstable.
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